5-HTP and Creatine for Depression R33 Phase
Eligible age
18–65 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma serotonin levels.
Sponsor: University of Utah
You may qualify if…
- ✓ Adults age 18-65 years inclusive
- ✓ Current diagnosis of MDD identified by the MINI (Mini Neuropsychiatric Interview)
- ✓ Current HAM-D17 score of \>= 16
- ✓ Adequate adherence to any FDA approved SSRI or SNRI for at least 8 weeks
- ✓ Right-handed
- ✓ Residing at \> 4000 ft for at least 12 weeks
You may not qualify if…
- ✕ Any non-MDD and non-anxiety psychiatric diagnosis, as identified by the MINI
- ✕ History of or current diagnosis of renal disease, such as chronic renal failure, acute renal failure or end stage renal disease
- ✕ Current colitis or diverticulitis
- ✕ History of or current pulmonary disease (except well controlled asthma)
- ✕ Current smoking
- ✕ History of cardiac disease or QTc \> 500ms
- ✕ History of fibromyalgia or any rheumatological condition
- ✕ History of or current seizure disorder
Where it's recruiting
Salt Lake City
Source: ClinicalTrials.gov · NCT05895747 · last updated 2025-08-08